論文

査読有り
2017年

Effect of Intranasal Administration of Galanin-like Peptide (GALP) on Body Weight and Hepatic Lipids Accumulation in Mice with Diet-induced Obesity

CURRENT PHARMACEUTICAL DESIGN
  • Satoshi Hirako
  • ,
  • Nobuhiro Wada
  • ,
  • Haruaki Kageyama
  • ,
  • Fumiko Takenoya
  • ,
  • Hyounju Kim
  • ,
  • Yuzuru Iizuka
  • ,
  • Akiyo Matsumoto
  • ,
  • Mai Okabe
  • ,
  • Seiji Shioda

23
25
開始ページ
3751
終了ページ
3756
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.2174/1381612823666170321095950
出版者・発行元
BENTHAM SCIENCE PUBL LTD

Galanin-like peptide (GALP) is a neuropeptide involved in the regulation of food intake behavior, body weight and energy metabolism. In previous studies, we demonstrated that the intranasal administration of GALP has weight loss effects, although the mechanism of this action was not clarified. The aim of this study was to demonstrate the functional significance of GALP on lipid metabolism in the liver. Mice were fed a high fat diet to cause diet-induced obesity (DIO) and then administered GALP intranasally for 2 weeks (experimental), or vehicle (control). Body weights, along with lipid levels in the plasma and liver, and lipid metabolism-related gene expression in the liver were subsequently measured. Body weight gain was decreased by the GALP treatment compared to the control group. Lipid droplet levels in hepatocytes and hepatic triglyceride levels were decreased in the GALP group compared with the vehicle group, whereas hepatic fatty acid beta-oxidation-related gene mRNA levels were increased in the GALP group. These results suggest that the intranasal administration of GALP has an inhibitory effect on lipid accumulation in the liver.

Web of Science ® 被引用回数 : 2

リンク情報
DOI
https://doi.org/10.2174/1381612823666170321095950
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/28325141
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000411908000013&DestApp=WOS_CPL

エクスポート
BibTeX RIS